Executive Director, Early Assets

The Executive Director, Early Assets will report to the Vice President, Value & Evidence Strategy (VESt) and will be responsible for developing, leading, and executing the medical strategy and scientific engagement for multiple early stage clinical programs, including assets being developed for hypertension, Alzheimer’s disease, diabetes, and NASH. The successful candidate will serve as the primary point of contact for Clinical Development, New Product Commercialization and Global Commercial and Market Access teams and ensure that the Medical Affairs perspective and the voice of the patient and health care provider are incorporated into early development and commercialization strategies.

Key Responsibilities

• Provide strategic and scientific leadership to and define global medical affairs strategy for early-stage clinical programs
• Serve as a key member of the product development teams and meaningfully impact clinical development plans, study design, and data interpretation
• Lead and execute global scientific engagement strategy and drive excellence in scientific engagement with all key stakeholders
• Develop, initiate, and maintain strong relationships with international scientific leaders and key stakeholders to enhance awareness of Alnylam’s early asset portfolio.
• Organize and manage global expert events (advisory boards, expert panels, symposia)
• Provide strategic medical insights into R&D and commercialization strategies including profiling patient pathways, mapping treatment landscape, and understanding prescriber patterns and dynamics
• Serve as the Medical Affairs lead for strategic partnerships
• Partner with VESt to develop and execute against integrated evidence generation plans
• Partner with medical communications team to ensure the development of a global communications strategy and execution of timely and high quality communication of scientific data (publication and medical congress)
• Partner with medical training team to develop and deliver high quality scientific and skill-based training to medical team across regions
• Liaise with global and regional medical affairs to ensure medical insights from all key markets are integrated into and inform product development
• Represent medical affairs at appropriate leadership and development forums

Qualifications

• MD, DO or equivalent ex-US medical degree
• 10+ years of demonstrated high-level professional knowledge and skills in the areas of medical affairs and R&D, especially familiarity with early clinical development, in the pharmaceutical or biotech industry
• 5+ years in leading teams in medical affairs or early clinical development
• Deep therapeutic area knowledge and experience in Cardiometabolic Diseases preferred
• Extensive knowledge of the latest regulatory, policy, and technology developments
• Proven track record of comprehensive global scientific engagement strategy including scientific congresses, external experts and panels, symposia, etc.
• Experience with RWE, diagnostics, translational work, and digital innovations
• Demonstrated expertise in informing R&D and commercialization strategies including patient pathways and mapping treatment landscape
• Proven record of close alignment with Clinical Development and contribution to CDP, data interpretation and dissemination
• Experience supporting due diligence for Business Development and serving as a medical expert for integrated asset planning, and building medical assessment framework
• High degree of professionalism, maturity, and confidentiality
• Strong written and verbal communication skills as well as strong leadership and interpersonal skills
• Demonstrated reputation as a well-respected, dynamic team leader, and player-coach
• Ability to deliver on company global program goals and objectives as they pertain to medical affairs
• Ability to affect positive organizational change at the company and team levels

About Alnylam: Alnylam Pharmaceuticals (Nasdaq: ALNY) has led the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare and more prevalent diseases. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach to treating diseases at their genetic source by “interfering” with mRNA that cause or contribute to disease. Since our founding in 2002, Alnylam has led the RNAi Revolution and continues to turn scientific possibility into reality.

Our culture: Our people-first culture is guided by our core values: fiercely innovative, open culture, purposeful urgency, passion for excellence, and commitment to people, and these values influence how we work and the business decisions we make. Thanks to feedback from our employees over the years, we’ve been fortunate to be named a top employer around the world. Alnylam is extremely proud to have been recognized as the #1 Large Employer by Boston Globe Top Places to Work in 2023 for the third consecutive year, one of Science Magazine’s Top Biopharma Employers, one of America's Most Responsible Companies for 2024 by Newsweek, a Fast Company Best Workplace for Innovators, and a Great Place to Work in Canada, France, Italy, Spain, Switzerland, and UK – among others.

At Alnylam, we commit to an inclusive recruitment process and equal employment opportunity. We are dedicated to building an environment where employees can feel that they belong, can bring their authentic selves to work, and achieve to their full potential. By empowering employees to embrace their unique differences at work, our business grows stronger with advanced and original thinking, allowing us to bring groundbreaking medicines to patients. Qualified applicants will receive consideration for employment without regard to their race, color, religion, age, sex, sexual orientation, gender identity or expression, national origin, ethnicity, marital status, protected veteran status, disability, or any other characteristics prohibited by law.